S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
US Dollar Replaced By "Biden Bucks"? (Ad)

Unsure How to Play the Pandemic? Buy the 'GERM' ETF

Unsure How to Play the Pandemic? Buy the GERM ETF

For the better part of this year investors have been trying to figure out ways to make money from companies that are benefitting from the pandemic. Technology stocks tied to the remote workforce theme have been popular and performed well. Several consumer products companies have also been clear winners.

But in the health care space, the picture isn't as clear. Purchasing the stock of a company competing to develop a viable COVID-19 vaccine or treatment is a bit of a crapshoot. Who will win the race? Will multiple winners emerge?

In the highly volatile biotechnology industry, the headline risk is already immense. One bad trial can sink a stock. A positive FDA review can send another stock flying.

When it comes to picking coronavirus-related biotech stocks, there are elements of both skill and luck. Investors who are not sure where to allocate their funds may want to consider the newly launched 'GERM' exchange-traded fund.

What is the 'GERM' ETF?

The ETF Managers Group (ETFMG) Treatments, Testing, and Advancement ETF debuted on the NYSE Arca exchange on June 18th. The fund's name is a mouthful and is more easily identified by its ticker symbol GERM.

The 'GERM' ETF offers exposure to a range of biotech and other health care companies that are involved in the testing and treatment of infectious diseases. The fund group has targeted 63 U.S. listed companies that are considered leaders in advancing the world's vaccines, therapies, and testing techniques.

Roughly two-thirds of the ETF is invested in treatment companies with the remaining one-third in diagnostic companies. The funds top holdings include some recognizable names that have been frequent COVID-19 headliners.


Moderna, one of the leaders in the race to develop a coronavirus vaccine, is the top holding. German biotech company BioNTech SE is next. It is partnered with Pfizer on the development of an mRNA vaccine. The duo is slated to have phase 3 results as soon as the end of October. Novavax, which is also in a final stage vaccine trial, is another top GERM holding.

In the testing space, well-known diagnostics companies Laboratory Corp and Quest Diagnostics are among the fund's largest positions.

GERM Fund Also a Play on Future Infectious Disease Outbreaks

The 'GERM' fund is not only a diversified way to spread out your bets among a basket of COVID-19 plays but has potential as a long-term play as well. Why? Although COVID-19 is the most pressing global health care concern, we are unfortunately sure to see more worldwide health threats.

According to the World Health Organization, there are currently 20 pandemics and epidemics impacting the world today. From January 2011 to January 2018, there were 36 epidemic events in the U.S. alone.

And as the world becomes more interconnected through trade and travel, the likelihood of continued disease outbreaks is high. This means that health care companies around the globe will be working on vaccines, treatments, and diagnostics for many years to come—and well beyond the coronavirus.

Transparency Market Research forecasted that the global vaccine market will grow 11% annually from 2016 to 2024 and become a $72.5 billion market. Whether as an immediate play or a long-term play on global vaccines, investors will want some exposure to this growth. The 'GERM' ETF is a good place to start.

Is the 'GERM' ETF a Good Buy Here?

The newborn GERM fund is undoubtedly small with assets under management (AUM) of around $53 million and relatively light trading volume. However, there appears to be ample liquidity which should only improve over time.

The 'GERM' ETF began trading at $25.30 in mid-June. Within about a month, it shot up nearly 40% as investors looking to get their hands on anything pandemic related scooped up shares. By early September, however, the fund's price fell back below its June debut price as the recent market volatility began to set in.

'GERM' has since staged a bit of a rebound and is trading around $27.50. And despite the hangover from the initial buzz around the fund's launch, the fund is still packed with plenty of growth potential. The recent pullback looks to be a good entry point for investors looking for a unique way to gain exposure to companies on the front lines of the COVID-19 battle and future infectious disease outbreaks.

The 'GERM' ETF is not cheap as it comes with a 68-basis point expense ratio. But given the growth outlook for the global vaccine, treatment, and diagnostic markets, it may be well worth the price.

As the world continues to grapple with the testing and treatment of emerging infectious diseases, this may be one GERM you're glad you have.

 

 

7 Dividend Aristocrats to Help You Take the Bite Out of the Bear

Investing in a bull market is fun and relatively easy. When the major indexes are hitting new highs seemingly every day, it's easy to find stocks to buy. By contrast, investing in a bear market may not be as enjoyable. But it's necessary, and when you have a strategy it doesn't have to be hard.

One timeless bear market strategy is to buy dividend stocks. And for investors looking to take even more risk out of this strategy, investors can elect to buy a group of stocks known as dividend aristocrats. These are companies that have a history of issuing, and growing, its dividend year – after year – after year. In fact, to be a member of this exclusive group, a company must have increased its dividend every year for at least 25 consecutive years.

In this special presentation, we'll analyze seven dividend aristocrats who are giving investors a good balance between growth and value. This makes them strong additions to your portfolio as part of a defensive strategy to weather a recession.

Here are 7 dividend aristocrats that can help your portfolio thrive in a bear market.

View the "7 Dividend Aristocrats to Help You Take the Bite Out of the Bear".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastInvesting in What You Know Has Changed

What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.